KKR
QGEN
The rumor mill has entered overdrive
Qiagen is having one of those classic public-company moments where the stock starts acting like there’s a wedding invitation in the mail. Bloomberg reported that KKR, EQT and Advent are among the private equity firms looking at a possible takeover of the molecular diagnostics company, and Qiagen shares popped 10.5% in the prior session on the speculation.
Not just a one-off flirtation
This isn’t brand-new gossip. Qiagen has been running a strategic review since at least January, when the company first started kicking around options that could include a sale. In March, CEO Thierry Bernard said Qiagen had brought in Moelis and Goldman Sachs to help steer the process, which is basically the corporate equivalent of calling in a professional matchmaker.
Why investors are leaning in
A few things make this more than random deal chatter:
- Some potential buyers are reportedly thinking about offers of at least $50 per share.
- Bernard’s planned departure, disclosed in November 2025, may remove a hurdle that had been hanging over a deal.
- Life sciences M&A is still very much alive, with peers like Merck KGaA and Danaher making big acquisition moves this year.
The catch: nothing is real until it is
For now, the discussions are still preliminary. No one has actually lobbed a formal bid, and the company’s recent results weren’t exactly the stuff of fireworks — first-quarter adjusted EPS came in at 54 cents on $492 million of revenue, while 2026 guidance landed a bit below consensus. Big picture: Qiagen has the kind of profile that can keep the rumor machine humming, but investors still need an actual offer before they can cash the check.